Why Servier’s FIREFLY-2 enrollment milestone could reshape pediatric glioma treatment
OJEMDA is already approved after relapse. FIREFLY-2 asks whether Servier can move targeted pLGG therapy earlier.
Pharma & Biotech
Pharma & Biotech
Why Servier’s $2.5bn acquisition of Day One Biopharmaceuticals could reshape the pediatric glioma treatment landscape
Servier plans a $2.5B acquisition of Day One Biopharmaceuticals to expand its rare oncology pipeline. Discover what the deal means for pediatric glioma.
Pharma & Biotech
Ipsen moves closer to EU approval for Ojemda in BRAF-driven childhood brain tumors
Ipsen nears EU approval for Ojemda in BRAF-driven pediatric glioma. Explore regulatory impact, clinical implications, and long-term risks.